# An Exploratory Study of Obinutuzumab β in the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy

> **NCT07696377** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhongming Qiu** · enrollment: 24 (estimated)

## Conditions studied

- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Obinutuzumab β

## Interventions

- **DRUG:** Obinutuzumab β

## Key facts

- **NCT ID:** NCT07696377
- **Lead sponsor:** Zhongming Qiu
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-15
- **Primary completion:** 2030-01-30
- **Final completion:** 2031-02-28
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07696377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07696377, "An Exploratory Study of Obinutuzumab β in the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07696377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*